Last reviewed · How we verify
CM082 plus paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CM082 plus paclitaxel (CM082 plus paclitaxel) — AnewPharma.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CM082 plus paclitaxel TARGET | CM082 plus paclitaxel | AnewPharma | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CM082 plus paclitaxel CI watch — RSS
- CM082 plus paclitaxel CI watch — Atom
- CM082 plus paclitaxel CI watch — JSON
- CM082 plus paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). CM082 plus paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/cm082-plus-paclitaxel. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing